大洋生物(003017) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥242,531,168.58, representing a year-on-year increase of 33.39%[5] - The net profit attributable to shareholders for Q3 2022 was ¥12,759,085.37, a decrease of 24.73% compared to the same period last year[5] - The basic earnings per share for Q3 2022 was ¥0.21, down 25.00% year-on-year[5] - Total operating revenue for Q3 2022 reached ¥735,173,544.19, an increase of 29.5% compared to ¥567,734,774.83 in Q3 2021[18] - The net profit for the third quarter of 2022 was CNY 50,100,877.55, a decrease of 28% compared to CNY 69,485,757.87 in the same period last year[19] - The total revenue from operating activities was CNY 707,227,132.03, up 21.2% from CNY 583,805,084.65 in the previous year[20] - The company reported a total comprehensive income of CNY 50,100,877.55 for the quarter, reflecting a decrease from CNY 69,485,757.87 in the previous year[19] Assets and Liabilities - Total assets at the end of Q3 2022 amounted to ¥1,401,617,860.79, reflecting a 1.98% increase from the end of the previous year[5] - Total current assets as of September 30, 2022, were ¥668,092,074.40, a decrease of 10% from ¥742,699,144.12 at the beginning of the year[16] - Total liabilities increased to ¥483,225,644.86, up 26.1% from ¥383,637,364.33 at the start of the year[16] - Total equity attributable to shareholders decreased to ¥918,392,215.93 from ¥990,709,384.09, a decline of 7.3%[16] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥60,849,462.15, showing a slight decrease of 0.29%[5] - The cash flow from operating activities showed a net increase of CNY 60,849,462.15, slightly down from CNY 61,025,112.94 in the previous year[20] - The cash flow from investment activities resulted in a net outflow of CNY 119,529,791.00, worsening from a net outflow of CNY 53,144,434.47 in the previous year[21] - The cash and cash equivalents net increase decreased by 192.80% to -¥87,936,337, due to reduced cash flow from investment activities[9] - Cash and cash equivalents decreased to ¥46,555,246.48 from ¥131,883,363.13, a decline of 64.7%[16] Operating Costs and Expenses - The company's operating costs increased by 41.88% to ¥630,401,867 due to rising raw material prices for main products[9] - Total operating costs for Q3 2022 were ¥706,453,483.97, up 38.3% from ¥510,878,636.15 in the same period last year[18] - R&D expenses rose by 44.45% to ¥26,378,606, attributed to new R&D project investments[9] - Research and development expenses increased to ¥26,378,606.21, representing a 44.5% rise from ¥18,261,132.56 in the previous year[18] Investments and Gains - The company recognized a total of ¥1,456,124.29 in non-recurring gains and losses for the current period[6] - Investment income fell by 63.54% to ¥3,190,358, primarily due to reduced returns from RMB financial products and foreign exchange forward contracts[9] - The net cash flow from investment activities decreased by 124.91% to -¥119,529,791, reflecting increased net investments in structured deposits[9] Borrowings and Financial Position - The company’s short-term borrowings increased by 69.00% to ¥235,026,250.00 due to liquidity needs[8] - Financial expenses decreased by 65.13% to ¥1,008,386, mainly due to increased foreign exchange gains[9] - The deferred income tax liabilities increased by 70.68% to ¥27,667,039 due to one-time deductions for equipment[9] Other Notable Changes - The company reported a significant increase in accounts receivable by 49.12%, reaching ¥51,093,685.21[8] - The company reported a significant increase in credit impairment losses by 701.30% to -¥629,662, reflecting higher bad debt provisions[9] - The deferred income increased by 31.17% to ¥12,586,885, mainly from government subsidies related to assets[9] - The company signed an investment framework agreement with the Shandong Linshu Economic Development Zone for a potassium carbonate project on September 26, 2022[13] - The company did not conduct any audited review of the third-quarter report[22]